Skip to main content
    E

    Evaxion Biotech AS (EVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.78
    +0.01 (+0.36%)

    Market Cap: $25.27M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Evaxion Biotech AS (EVAX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Evaxion Biotech AS (EVAX) has a market cap of $25.27M and an enterprise value of $16.58M. Its share count is down 62.27% from a year earlier. Revenue grew 127.84% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 34.38% below the market cap, as cash exceeds debt.

    Market Cap$25.27M
    Enterprise Value$16.58M
    Latest price (Nov 17, 2026)$2.78

    Key Dates

    The next earnings report is set for Nov 19, 2026, before the open.

    Next Earnings DateNov 19, 2026, before the open
    Last Earnings DateAug 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 95.00% in the quarter ended Jun 30, 2026.

    Shares Outstanding417.01K
    Shares Change (YoY)-62.27%
    Shares Change (QoQ)-95.00%

    Valuation Ratios

    Sales and book value multiples are 0.2x and 0.1x. Its year-end P/S ranged from 0.7x to 321.0x from 2023 to 2025.

    P/S Ratio0.2x
    P/B Ratio0.1x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 0.4x free cash flow.

    EV / Sales2.2x
    EV / FCF0.4x

    Price Statistics

    The stock is down 49.08% over 52 weeks and trades 10.61% below its 50-day average.

    Beta (1Y)0.45
    52-Week Change-49.08%
    1-Month Change-16.52%
    3-Month Change-11.75%
    6-Month Change-30.15%
    5-Year Change-99.23%
    Total Return (1Y)-49.08%
    Total Return (3Y CAGR)-57.60%
    Total Return (5Y CAGR)-60.05%
    Return vs SPY (1Y)-58.71%
    Max Drawdown (1Y)-58.67%
    Max Drawdown (3Y)-97.55%
    Sharpe Ratio (1Y)-0.81
    Correlation with SPY (1Y)0.08
    50-Day Average$3.11
    200-Day Average$3.43
    52-Week Range$2.65 to $6.92
    RSI (14 Days)43.1
    Average Volume (20 Days)89.97K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.06x current liabilities, and total debt is 0.56x shareholder equity.

    Current Ratio5.06x
    Quick Ratio5.06x
    Debt / Equity0.56x
    Interest Coverage-4.40x

    Returns and Efficiency

    Return on invested capital is -79.46% and return on equity is -90.79% over the last 12 months.

    Return on Equity (ROE)-90.79%
    Return on Assets (ROA)-44.65%
    Return on Invested Capital (ROIC)-79.46%
    Asset Turnover0.36x
    Receivables Turnover8.26x

    Scores

    EVAX has an Altman Z-Score of -10.62, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-10.62
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $7.51M over the last 12 months.

    Revenue$7.51M
    Revenue Growth (YoY)+127.84%
    Operating Income-$8.69M
    Pretax Income-$9.59M
    Net Income-$8.65M
    Reported EPS (TTM)-$0.51

    Trailing 12 months through Jun 30, 2026.

    Balance Sheet

    Shareholder equity funds 49.17% of the $19.38M in total assets.

    Cash and Equivalents$14.00M
    Total Debt$5.31M
    Net Cash$8.69M
    Working Capital$12.72M
    Shareholder Equity$9.53M
    Total Assets$19.38M
    Total Liabilities$9.85M

    Balance sheet as of Jun 30, 2026.

    Cash Flow

    Capital Expenditures$11.03K
    FCF Per Share-$1.91

    Trailing 12 months through Jun 30, 2026.

    Margins

    The operating margin is -115.64%.

    Operating Margin-115.64%
    Pretax Margin-127.67%
    Net Margin-115.15%

    Dividends and Yields

    EVAX does not pay a dividend. Its free cash flow yield is -1515.96%.

    FCF Yield-1515.96%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-5 reverse split on Jan 14, 2025.

    Last Split DateJan 14, 2025
    Split TypeReverse split
    Split Ratio1:5

    Peer Position

    Against 3 similar companies, EVAX has the lowest P/S.

    P/S Ratio0.2x vs 2.1x median
    ROIC-79.46% vs -102.82% median
    Revenue Growth (Trailing 4 Quarters, YoY)+127.84% vs -100.00% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About EVAX

    What is EVAX's market cap?

    Evaxion Biotech AS has a market cap of $25.27M. Its enterprise value, which adds debt and subtracts cash, is $16.58M.

    How many shares of EVAX are outstanding?

    Evaxion Biotech AS has 417.01K shares outstanding. The count is down 62.27% from a year earlier.

    Does EVAX pay a dividend?

    No. Evaxion Biotech AS does not pay a dividend.

    How much debt does EVAX have?

    Evaxion Biotech AS has $5.31M of total debt and $14.00M of cash and equivalents, a net cash position of $8.69M.